A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial Lines
← catalyst calendarNCT04821089 · readout in 12 d
Sponsored by Ipsen (industry) · IPN.PA — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
727estimated
Sites
10
Countries
France, Germany
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-04-06 | actual | When the study began enrolling |
| Primary completion | 2026-08-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-08-19 | estimated | The whole study's end, after follow-up |
| First posted | 2021-03-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Moderate to Severe Upper Facial Lines
Interventions
- Biological: Corabotase
- Biological: IPN10200 Placebo
- Biological: Dysport
Primary outcomes
what the primary-completion date above is the date OFIncidence of treatment emergent adverse events (TEAEs) at each dose
measured From the baseline to the end of the study (9 months)
Incidence of serious adverse events (SAEs) at each dose
measured From the baseline to the end of the study (9 months)
Incidence of Adverse Events (AEs) (or SAEs) leading to withdrawals and Adverse Events of Special Interest (AESIs)
measured From the baseline to the end of the study (9 months)
Response to treatment at Stage 2 for the FHL group
measured At Week 4
Response to treatment at Stage 2 for the glabellar lines (GL)+ FHL group
measured At Week 4
Response to treatment at Stage 2 for the LCL group
measured At Week 4
Percentage of Participants With Clinically Significant Changes from baseline in Vital Signs
measured From the baseline to the end of the study (6 years, 5 months)
Percentage of participants with clinically significant Change from baseline in 12-lead Electrocardiogram (ECG) readings
measured From the baseline to the end of the study (6 years, 5 months)
Percentage of participants with clinically significant change from baseline in facial and focused neurological/physical examination.
measured From the baseline to the end of the study (6 years, 5 months)
Permalink · IPN.PA's whole pipeline · Catalyst calendar · Every registered study · What changed